Flotte TRE-i-C. Revisiting the “New” inflammatory toxicities of adeno-associated virus vectors. Hum Gene Ther, 2020; 31:398–399.
2.
NonnenmacherM, WeberT. Intracellular transport of recombinant adeno-associated virus vectors. Gene Ther, 2012; 19:649–658.
3.
Louis JeuneV, JoergensenJA, HajjarRJ, et al.Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapy. Hum Gene Ther Methods, 2013; 24:59–67.
4.
GreenbergB, ButlerJ, FelkerGM, et al.Prevalence of AAV1 neutralizing antibodies and consequences for a clinical trial of gene transfer for advanced heart failure. Gene Ther, 2016; 23:313–319.
5.
WeberT. Anti-AAV antibodies in AAV gene therapy: current challenges and possible solutions. Front Immunol, 2021; 12:658399.
6.
KruzikA, FetahagicD, HartliebB, et al.Prevalence of anti-adeno-associated virus immune responses in international cohorts of healthy donors. Mol Ther Methods Clin Dev, 2019; 14:126–133.
7.
CalcedoR, VandenbergheLH, GaoG, et al.Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J Infect Dis, 2009; 199:381–390.
8.
BoutinS, MonteilhetV, VeronP, et al.Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum Gene Ther, 2010; 21:704–712.
9.
NonnenmacherM, van BakelH, HajjarRJ, et al.High capsid-genome correlation facilitates creation of AAV libraries for directed evolution. Mol Ther, 2015; 23:675–682.
10.
NonnenmacherM, WeberT. Adeno-associated virus 2 infection requires endocytosis through the CLIC/GEEC pathway. Cell Host Microbe, 2011; 10:563–576.
11.
MuhuriM, MaedaY, MaH, et al.Overcoming innate immune barriers that impede AAV gene therapy vectors. J Clin Invest, 2021; 131:e143780.
12.
RussellS, BennettJ, WellmanJA, et al.Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet, 2017; 390:849–860.
13.
MuellerC, BerryJD, McKenna-YasekDM, et al.SOD1 suppression with adeno-associated virus and microRNA in familial ALS. N Engl J Med, 2020; 383:151–158.
14.
MendellJR, Al-ZaidyS, ShellR, et al.Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med, 2017; 377:1713–1722.
15.
MonteilhetV, SahebS, BoutinS, et al.A 10 patient case report on the impact of plasmapheresis upon neutralizing factors against adeno-associated virus (AAV) types 1, 2, 6, and 8. Mol Ther, 2011; 19:2084–2091.
16.
OrlowskiA, KatzMG, GubaraSM, et al.Successful transduction with AAV vectors after selective depletion of anti-AAV antibodies by immunoadsorption. Mol Ther Methods Clin Dev, 2020; 16:192–203.
17.
BertinB, VeronP, LeborgneC, et al.Capsid-specific removal of circulating antibodies to adeno-associated virus vectors. Sci Rep, 2020; 10:864.
18.
MingozziF, AnguelaXM, PavaniG, et al.Overcoming preexisting humoral immunity to AAV using capsid decoys. Sci Transl Med, 2013; 5:194ra192.
19.
PeiX, EarleyLF, HeY, et al.Efficient capsid antigen presentation from adeno-associated virus empty virions in vivo. Front Immunol, 2018; 9:844.
20.
MartinoAT, MarkusicDM. Immune response mechanisms against AAV vectors in animal models. Mol Ther Methods Clin Dev, 2020; 17:198–208.
21.
HerzogRW, BiswasM. Neutralizing the neutralizers in AAV gene therapy. Mol Ther, 2020; 28:1741–1742.
22.
LeborgneC, BarbonE, AlexanderJM, et al.IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV neutralizing antibodies. Nat Med, 2020; 26:1096–1101.
23.
ElmoreZC, OhDK, SimonKE, et al.Rescuing AAV gene transfer from neutralizing antibodies with an IgG-degrading enzyme. JCI Insight, 2020; 5:e139881.
24.
GurungS, PerocheauD, TouramanidouL, et al.The exosome journey: from biogenesis to uptake and intracellular signalling. Cell Commun Signal, 2021; 19:47.
25.
FengZ, HensleyL, McKnightKL, et al.A pathogenic picornavirus acquires an envelope by hijacking cellular membranes. Nature, 2013; 496:367–371.
26.
Altan-BonnetN, PeralesC, DomingoE. Extracellular vesicles: vehicles of en bloc viral transmission. Virus Res, 2019; 265:143–149.
27.
RamakrishnaiahV, ThumannC, FofanaI, et al.Exosome-mediated transmission of hepatitis C virus between human hepatoma Huh7.5 cells. Proc Natl Acad Sci U S A, 2013; 110:13109–13113.
28.
MaguireCA, BalajL, SivaramanS, et al.Microvesicle-associated AAV vector as a novel gene delivery system. Mol Ther, 2012; 20:960–971.
29.
MelianiA, BoisgeraultF, FitzpatrickZ, et al.Enhanced liver gene transfer and evasion of preexisting humoral immunity with exosome-enveloped AAV vectors. Blood Adv, 2017; 1:2019–2031.
30.
WassmerSJ, CarvalhoLS, GyorgyB, et al.Exosome-associated AAV2 vector mediates robust gene delivery into the murine retina upon intravitreal injection. Sci Rep, 2017; 7:45329.
31.
GyorgyB, FitzpatrickZ, CrommentuijnMH, et al.Naturally enveloped AAV vectors for shielding neutralizing antibodies and robust gene delivery in vivo. Biomaterials, 2014; 35:7598–7609.
32.
ChengM, DietzL, GongY, et al.Neutralizing antibody evasion and transduction with purified extracellular vesicle-enveloped adeno-associated virus vectors. Hum Gene Ther, 2021; 32:1457–1470.
33.
SchillerLT, Lemus-DiazN, Rinaldi FerreiraR, et al.Enhanced production of exosome-associated AAV by overexpression of the tetraspanin CD9. Mol Ther Methods Clin Dev, 2018; 9:278–287.
34.
OgdenPJ, KelsicED, SinaiS, et al.Comprehensive AAV capsid fitness landscape reveals a viral gene and enables machine-guided design. Science, 2019; 366:1139–1143.
35.
GalibertL, HyvonenA, ErikssonRAE, et al.Functional roles of the membrane-associated AAV protein MAAP. Sci Rep, 2021; 11:21698.
36.
LiuB, LiZ, HuangS, et al.AAV-containing exosomes as a novel vector for improved gene delivery to lung cancer cells. Front Cell Dev Biol, 2021; 9:707607.
37.
GyorgyB, SageC, IndzhykulianAA, et al.Rescue of hearing by gene delivery to inner-ear hair cells using exosome-associated AAV. Mol Ther, 2017; 25:379–391.
38.
HudryE, MartinC, GandhiS, et al.Exosome-associated AAV vector as a robust and convenient neuroscience tool. Gene Ther, 2016; 23:380–392.
39.
WangW, LiuJ, YangM, et al.Intravitreal injection of an exosome-associated adeno-associated viral vector enhances retinoschisin 1 gene transduction in the mouse retina. Hum Gene Ther, 2021; 32:707–716.
40.
BreuerCB, HanlonKS, NatasanJS, et al.In vivo engineering of lymphocytes after systemic exosome-associated AAV delivery. Sci Rep, 2020; 10:4544.
41.
DaiS, WeiD, WuZ, et al.Phase I clinical trial of autologous ascites-derived exosomes combined with GM-CSF for colorectal cancer. Mol Ther, 2008; 16:782–790.
42.
MorseMA, GarstJ, OsadaT, et al.A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J Transl Med, 2005; 3:9.
43.
EscudierB, DorvalT, ChaputN, et al.Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial. J Transl Med, 2005; 3:10.
44.
MignotG, RouxS, TheryC, et al.Prospects for exosomes in immunotherapy of cancer. J Cell Mol Med, 2006; 10:376–388.
